MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.90
+0.16
+1.44%
Opening 15:13 07/01 EDT
OPEN
10.70
PREV CLOSE
10.74
HIGH
10.97
LOW
10.56
VOLUME
2.46M
TURNOVER
17.29M
52 WEEK HIGH
12.63
52 WEEK LOW
5.91
MARKET CAP
3.05B
P/E (TTM)
-11.2831
1D
5D
1M
3M
1Y
5Y
Short Volatility Alert: Amicus Therapeutics, Inc.
On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88.  The overall sentiment for FOLD has been Bearish.
Benzinga · 06/22 14:18
Why Is Amicus Therapeutics (FOLD) Up 25.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/08 15:30
Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, Ju...
GlobeNewswire · 06/08 11:00
Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 06/05 14:18
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to ...
Benzinga · 05/31 19:42
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
Zacks · 05/31 18:27
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
FDA Extends Review Of Amicus Therapeutics' AT-GAA For The Treatment Of Pompe Disease By Three Months
The U.S.
Benzinga · 05/10 21:18
More
No Data
Learn about the latest financial forecast of FOLD. Analyze the recent business situations of Amicus Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FOLD stock price target is 14.22 with a high estimate of 20.00 and a low estimate of 10.00.
High20.00
Average14.22
Low10.00
Current 10.90
EPS
Actual
Estimate
-0.24-0.18-0.12-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 327
Institutional Holdings: 351.53M
% Owned: 125.47%
Shares Outstanding: 280.16M
TypeInstitutionsShares
Increased
63
17.47M
New
25
2.12M
Decreased
84
12.00M
Sold Out
29
4.50M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.45%
Pharmaceuticals & Medical Research
+0.72%
Key Executives
Chairman/Chief Executive Officer/Director
John Crowley
President/Chief Operating Officer/Director
Bradley Campbell
Chief Financial Officer
Daphne Quimi
Other
David Clark
Secretary
Ellen Rosenberg
Lead Director/Independent Director
Michael Raab
Independent Director
Lynn Bleil
Independent Director
Michael Kelly
Independent Director
Margaret Mcglynn
Independent Director
Eiry Roberts
Independent Director
Glenn Sblendorio
Independent Director
Craig Wheeler
Independent Director
Burke Whitman
No Data
No Data
About FOLD
Amicus Therapeutics, Inc. is a global biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company’s portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. The United States Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to AT-GAA for the treatment of late onset Pompe disease. Its pipeline includes gene therapy programs in rare, neurologic lysosomal disorders (LDs), specifically: CLN6, CLN3 and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder (CDD), Mucopolysaccharidosis Type IIIB (MPS IIIB), as well as in Mucopolysaccharidosis Type IIIA (MPS IIIA).

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.